NOT FOR DISTRIBUTION
Header cover image

Market Cap

Rp1.1t

Last Updated

2021/05/10 17:26 UTC

Data Sources

Company Financials

Executive Summary

PT Phapros, Tbk operates in the pharmaceutical and health care industry in Indonesia. More Details


Snowflake Analysis

Undervalued second-rate dividend payer.


Similar Companies

Share Price & News

How has Phapros's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PEHA is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PEHA's weekly volatility has decreased from 12% to 4% over the past year.


Market Performance


7 Day Return

0%

PEHA

1.3%

ID Pharmaceuticals

-0.5%

ID Market


1 Year Return

20.2%

PEHA

20.4%

ID Pharmaceuticals

22.3%

ID Market

Return vs Industry: PEHA matched the ID Pharmaceuticals industry which returned 20.4% over the past year.

Return vs Market: PEHA underperformed the ID Market which returned 22.3% over the past year.


Shareholder returns

PEHAIndustryMarket
7 Day0%1.3%-0.5%
30 Day0%-3.8%-2.7%
90 Day-10.4%-9.1%-5.5%
1 Year28.5%20.2%22.7%20.4%26.3%22.3%
3 Yearn/a2.3%-3.3%2.3%-5.4%
5 Yearn/a32.9%20.3%34.1%17.8%

Long-Term Price Volatility Vs. Market

How volatile is Phapros's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Phapros undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PEHA (IDR1250) is trading below our estimate of fair value (IDR5434.89)

Significantly Below Fair Value: PEHA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PEHA is good value based on its PE Ratio (11.5x) compared to the ID Pharmaceuticals industry average (25x).

PE vs Market: PEHA is good value based on its PE Ratio (11.5x) compared to the ID market (22.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PEHA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PEHA is good value based on its PB Ratio (1.5x) compared to the ID Pharmaceuticals industry average (2.4x).


Future Growth

How is Phapros forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Phapros has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Phapros performed over the past 5 years?

-6.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PEHA has high quality earnings.

Growing Profit Margin: PEHA's current net profit margins (9.1%) are higher than last year (8.6%).


Past Earnings Growth Analysis

Earnings Trend: PEHA's earnings have declined by 6.6% per year over the past 5 years.

Accelerating Growth: PEHA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PEHA had negative earnings growth (-4.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9%).


Return on Equity

High ROE: PEHA's Return on Equity (12.8%) is considered low.


Financial Health

How is Phapros's financial position?


Financial Position Analysis

Short Term Liabilities: PEHA's short term assets (IDR1,329.2B) do not cover its short term liabilities (IDR1,390.0B).

Long Term Liabilities: PEHA's short term assets (IDR1,329.2B) exceed its long term liabilities (IDR98.7B).


Debt to Equity History and Analysis

Debt Level: PEHA's debt to equity ratio (164.5%) is considered high.

Reducing Debt: Insufficient data to determine if PEHA's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: PEHA's debt is not well covered by operating cash flow (11.5%).

Interest Coverage: PEHA's interest payments on its debt are not well covered by EBIT (1.4x coverage).


Balance Sheet


Dividend

What is Phapros's current dividend yield, its reliability and sustainability?

6.80%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PEHA's dividend (6.8%) is higher than the bottom 25% of dividend payers in the ID market (1.15%).

High Dividend: PEHA's dividend (6.8%) is in the top 25% of dividend payers in the ID market (4.83%)


Stability and Growth of Payments

Stable Dividend: PEHA has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: PEHA has only been paying a dividend for 2 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (78.1%), PEHA's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Hadi Kardoko (44 yo)

0.92

Tenure

Mr. Hadi Kardoko has been President Director at PT Phapros, Tbk since June 2020. He served as General Manager of Manufacturing at PT Kimia Farma Tbk in 2018, as well as General Manager of Transformation Ma...


Leadership Team

Experienced Management: PEHA's management team is seasoned and experienced (5.1 years average tenure).


Board Members

Experienced Board: PEHA's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Phapros, Tbk's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PT Phapros, Tbk
  • Ticker: PEHA
  • Exchange: IDX
  • Founded: 1954
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Rp1.050t
  • Shares outstanding: 840.00m
  • Website: https://www.phapros.co.id

Number of Employees


Location

  • PT Phapros, Tbk
  • Rajawali Tower 17th Floor
  • 17th Floor
  • Jakarta
  • Jakarta Raya
  • 12950
  • Indonesia

Listings


Biography

PT Phapros, Tbk operates in the pharmaceutical and health care industry in Indonesia. The company operates through Over the Counter (OTC), Ethical, Generic Drugs Bearing, and Toll Manufacturing segments. I...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/10 17:26
End of Day Share Price2021/05/07 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.